Literature DB >> 8552437

Effect of an interleukin-1 receptor antagonist on the hemodynamic manifestations of group B streptococcal sepsis.

J D Vallette1, R N Goldberg, C Suguihara, T Del Moral, O Martinez, J Lin, R C Thompson, E Bancalari.   

Abstract

IL-1 is purported to be a proximal mediator in the cascade leading to septic shock. To characterize its hemodynamic effects and to ascertain whether its blockade would ameliorate the deleterious consequences of sepsis, an IL-1 receptor antagonist (IL-1ra) was administered to 16 anesthetized, mechanically ventilated piglets that received a continuous infusion of group B streptococci (GBS) (7.5 x 10(7) colony-forming units/kg/min). Systemic (Psa), pulmonary artery (Ppa), and wedge (Pwp) pressures and cardiac output were measured pre-GBS and every 30 min during GBS infusion. After 15 min of bacterial infusion the control group received normal saline, whereas the treatment group received a bolus of IL-1ra (40 mg/kg) followed by a continuous infusion of IL-1ra (60 micrograms/kg/min). In comparing IL-1ra-treated animals with controls from the 15-min GBS baseline to the succeeding septic study period (45-120 min), the following treatment effects were noted (120-min values shown): mean Psa remained elevated in treatment compared with control animals (12.7 +/- 2.5 versus 9 +/- 3.5 kPa; p < 0.001) as did CO (0.21 +/- 0.07 versus 0.13 +/- 0.08 L/min/kg; p < 0.001). Pwp decreased in the treatment compared to the control group over the study period (1 +/- 0.3 versus 1.6 +/- 0.7 kPa; p < 0.02). Mean Ppa and mean Pra were not different between groups over time. Median length of survival was significantly longer (p = 0.04) in treated (226 min) compared with control animals (150 min). These data suggest that IL-1 plays an important role in GBS sepsis and septic shock, and that IL-1ra may in part ameliorate the cardiovascular alterations associated with GBS sepsis in the neonate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8552437     DOI: 10.1203/00006450-199511000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

Review 1.  Recent advances in understanding the molecular basis of group B Streptococcus virulence.

Authors:  Heather C Maisey; Kelly S Doran; Victor Nizet
Journal:  Expert Rev Mol Med       Date:  2008-09-22       Impact factor: 5.600

Review 2.  Induction and termination of inflammatory signaling in group B streptococcal sepsis.

Authors:  Julia Wennekamp; Philipp Henneke
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

3.  A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy.

Authors:  R S McDuffie; J K Davies; K K Leslie; S Lee; M P Sherman; R S Gibbs
Journal:  Infect Dis Obstet Gynecol       Date:  2001

4.  Neonatal Group B Streptococcal Disease in Otherwise Healthy Infants: Failure of Specific Neonatal Immune Responses.

Authors:  Alessandro Borghesi; Mauro Stronati; Jacques Fellay
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.